Advanced Research in Breast Diseases and Histopathology

A special issue of Biomedicines (ISSN 2227-9059). This special issue belongs to the section "Cell Biology and Pathology".

Deadline for manuscript submissions: 31 July 2025 | Viewed by 417

Special Issue Editor


E-Mail
Guest Editor
Department of Oncology Propaedeutics, Medical University of Warsaw, 01-445 Warsaw, Poland
Interests: breast cancer; pathology; immunohistochemistry; cell biology

Special Issue Information

Dear Colleagues,

Breast tissue is uniquely sensitive to hormonal, genetic, and environmental factors throughout a person's life. These influences contribute to a dynamic environment where cellular and structural changes can lead to a variety of pathological conditions, including both benign and malignant lesions. Understanding the fundamental biological mechanisms underlying specific breast disorders is a key factor in improving diagnostic and therapeutic methods. Despite the advancements made in other branches of medicine, histopathological examination remains the gold standard in the diagnosis of breast diseases.

This Special Issue of Biomedicines will focus on current opportunities and challenges related to the pathology, molecular biology, and diagnosis of breast diseases, including breast cancer, with special attention given to novel biomarkers, prognostic factors, and diagnostic methods. Authors are welcome to submit original research and review articles.

Dr. Michał Budzik
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • breast cancer
  • breast diseases
  • histopathology
  • biomarkers
  • screening
  • diagnosis
  • early detection
  • tumor microenvironment
  • pathophysiology
  • molecular biology

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

30 pages, 1537 KiB  
Review
HER2-Positive Breast Cancer—Current Treatment Management and New Therapeutic Methods for Brain Metastasis
by Hanna Miski, Kamila Krupa, Michał Piotr Budzik, Andrzej Deptała and Anna Badowska-Kozakiewicz
Biomedicines 2025, 13(5), 1153; https://doi.org/10.3390/biomedicines13051153 - 9 May 2025
Viewed by 317
Abstract
Background: Breast cancer can be classified based on the immunohistochemistry (IHC) phenotypes, defined by the presence or absence of the main IHC markers. IHC phenotyping is important as it determines the prognosis and guides treatment. For example, human epidermal growth factor receptor [...] Read more.
Background: Breast cancer can be classified based on the immunohistochemistry (IHC) phenotypes, defined by the presence or absence of the main IHC markers. IHC phenotyping is important as it determines the prognosis and guides treatment. For example, human epidermal growth factor receptor 2 (HER2) overexpression, which triggers cell growth and division, is observed in HER2-positive breast cancer. Methods: The standard treatment is based on trastuzumab plus pertuzumab in combination with taxane chemotherapy. The possibility of developing metastases depends on those phenotypes. Approximately 25–50% of patients with HER2-positive breast cancer experience brain metastases. This aspect is especially important, as 20% of those patients die as a result. Results: Through the years, many advanced therapies have been introduced to treat brain metastases, including whole brain radiotherapy, stereotactic radiosurgery, and a tyrosine kinase inhibitor (TKI), neratinib. Nonetheless, this still remains a therapeutic challenge. Conclusions: In this review, we focus on the treatment and efficiency of therapies targeting HER2-positive breast cancer, mainly concentrating on the current and newly developed treatment options for brain metastases, such as trastuzumab deruxtecan and tucatinib. Full article
(This article belongs to the Special Issue Advanced Research in Breast Diseases and Histopathology)
Show Figures

Figure 1

Back to TopTop